Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Chicago Center for Diabetes Translation Research, Chicago, Illinois.
JAMA Netw Open. 2024 Nov 4;7(11):e2445316. doi: 10.1001/jamanetworkopen.2024.45316.
While continuous glucose monitoring (CGM) has been found to improve diabetes care processes and outcomes, adoption remains low.
To examine the association between CGM prescriptions and individual characteristics among patients with type 1 or 2 diabetes (T1D and T2D, respectively).
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cross-sectional study using electronic health record data for patients with T1D or T1D from 275 clinic sites nationwide between January 2014 and February 2021. All participating clinics were federally qualified health centers (FQHCs), the largest US system of primary care for vulnerable populations. Data were analyzed from September 2022 to August 2024.
Sociodemographic factors, clinical characteristics, and CGM prescription orders.
A total of 1168 patients with T1D (mean [SD] age, 41.8 [16.0] years; 600 [51.4%] male; 372 [31.9%] Black; 262 [22.4%] Hispanic, and 750 [64.2%] White patients) and 35 216 patients with T2D (mean [SD] age, 58.4 [13.1] years; 19 772 [56.1%] female; 12 030 [34.2%] Black; 12 979 [36.9%] Hispanic, and 20 413 [58.0] White patients) were included. Overall, CGM prescriptions were infrequent (129 [11.0%] for patients with T1D and 362 [1.0%] for those with T2D) but increased throughout the study period. Among patients with T1D, those who reported Hispanic ethnicity (odds ratio [OR], 0.30; 95% CI, 0.16-0.57), Black race (OR, 0.61; 95% CI, 0.38-0.99), or were uninsured (OR, 0.42; 95% CI, 0.23-0.74) had lower multivariable odds of receiving a CGM prescription than White or insured adults, respectively. Similar findings were observed among patients with T2D reporting Hispanic ethnicity (OR, 0.43; 95% CI, 0.32-0.57), Black race (OR, 0.76; 95% CI, 0.59-0.98), or being uninsured (OR, 0.42; 95% CI, 0.31-0.58), relative to their counterparts. Among patients with T2D, hemoglobin A1c values higher than 9.0% (OR, 3.17; 95% CI, 2.37-4.21) and a greater burden of diabetes complications were associated with higher odds of CGM prescription.
In this cross-sectional study of electronic health record data, rates of CGM prescription orders were low among FQHC patients with T1D and T2D. Disparities in CGM orders were observed among patients reporting Hispanic ethnicity, Black race, and those who lacked health insurance. Future research is needed to understand the causes of infrequent CGM orders in FQHCs and drivers of observed disparities in this vulnerable patient population.
虽然连续血糖监测(CGM)已被发现可改善糖尿病护理流程和结果,但采用率仍然很低。
研究 CGM 处方与 1 型或 2 型糖尿病(T1D 和 T2D,分别)患者个体特征之间的关联。
设计、设置和参与者:这是一项使用全国 275 个临床地点的电子健康记录数据进行的回顾性横断面研究,时间范围为 2014 年 1 月至 2021 年 2 月。所有参与的诊所均为联邦合格的健康中心(FQHC),这是美国最大的弱势群体初级保健系统。数据于 2022 年 9 月至 2024 年 8 月进行分析。
社会人口统计学因素、临床特征和 CGM 处方。
共纳入 1168 名 T1D 患者(平均[标准差]年龄 41.8[16.0]岁;600[51.4%]为男性;372[31.9%]为黑人;262[22.4%]为西班牙裔,750[64.2%]为白人患者)和 35216 名 T2D 患者(平均[标准差]年龄 58.4[13.1]岁;19772[56.1%]为女性;12030[34.2%]为黑人;12979[36.9%]为西班牙裔,20413[58.0%]为白人患者)。总体而言,CGM 处方的开具频率较低(T1D 患者为 129[11.0%],T2D 患者为 362[1.0%]),但在整个研究期间有所增加。在 T1D 患者中,报告西班牙裔血统(比值比[OR],0.30;95%CI,0.16-0.57)、黑人种族(OR,0.61;95%CI,0.38-0.99)或没有医疗保险(OR,0.42;95%CI,0.23-0.74)的患者,与白人或有保险的成年人相比,接受 CGM 处方的多变量可能性更低。在报告西班牙裔血统(OR,0.43;95%CI,0.32-0.57)、黑人种族(OR,0.76;95%CI,0.59-0.98)或没有医疗保险(OR,0.42;95%CI,0.31-0.58)的 T2D 患者中也观察到类似的发现。在 T2D 患者中,血红蛋白 A1c 值高于 9.0%(OR,3.17;95%CI,2.37-4.21)和糖尿病并发症负担较重与 CGM 处方的可能性更高相关。
在这项对电子健康记录数据的横断面研究中,FQHC 的 T1D 和 T2D 患者的 CGM 处方订单率较低。在报告西班牙裔、黑人和没有医疗保险的患者中,观察到 CGM 订单存在差异。需要进一步研究以了解 FQHC 中 CGM 订单频率较低的原因以及在这一脆弱患者群体中观察到的差异的驱动因素。